Immune-mediated approaches against COVID-19

HF Florindo, R Kleiner, D Vaskovich-Koubi… - Nature …, 2020 - nature.com
Abstract The coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). The long incubation period of this new virus, which …

COVID-19: drug targets and potential treatments

C Gil, T Ginex, I Maestro, V Nozal… - Journal of medicinal …, 2020 - ACS Publications
Currently, humans are immersed in a pandemic caused by the emerging severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …

Drug targets for corona virus: A systematic review

M Prajapat, P Sarma, N Shekhar, P Avti… - Indian journal of …, 2020 - journals.lww.com
Abstract The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21 th
century. However, the lack of specific drugs to prevent/treat an attack is a major need at this …

Overview of SARS-CoV-2 genome-encoded proteins

C Bai, Q Zhong, GF Gao - Science China Life Sciences, 2022 - Springer
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has spread rapidly
throughout the world. SARS-CoV-2 is an enveloped, plus-stranded RNA virus with a single …

Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review

S Mhatre, T Srivastava, S Naik, V Patravale - Phytomedicine, 2021 - Elsevier
Background The rapid spread of novel coronavirus called SARS-CoV-2 or nCoV has caused
countries all over the world to impose lockdowns and undertake stringent preventive …

Drug development and medicinal chemistry efforts toward SARS‐coronavirus and Covid‐19 therapeutics

AK Ghosh, M Brindisi, D Shahabi… - …, 2020 - Wiley Online Library
The COVID‐19 pandemic caused by SARS‐CoV‐2 infection is spreading at an alarming
rate and has created an unprecedented health emergency around the globe. There is no …

Approved antiviral drugs over the past 50 years

E De Clercq, G Li - Clinical microbiology reviews, 2016 - Am Soc Microbiol
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches

A Kumar, G Choudhir, SK Shukla… - Journal of …, 2021 - Taylor & Francis
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel corona virus that
causes corona virus disease 2019 (COVID-19). The COVID-19 rapidly spread across the …

In silico investigation of phytoconstituents from Indian medicinal herb 'Tinospora cordifolia (giloy)' against SARS-CoV-2 (COVID-19) by molecular dynamics approach

P Chowdhury - Journal of Biomolecular Structure and Dynamics, 2021 - Taylor & Francis
The recent appearance of COVID-19 virus has created a global crisis due to unavailability of
any vaccine or drug that can effectively and deterministically work against it. Naturally …

In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)

P Sarma, N Shekhar, M Prajapat, P Avti… - Journal of …, 2021 - Taylor & Francis
The N terminal domain (NTD) of Nucleocapsid protein (N protein) of coronavirus (CoV)
binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex …